The positive symptoms of schizophrenia (e.g., hallucinations, delusions) are a symptom domain of schizophrenia that affects approximately 83% of the 3.2 million diagnosed prevalent cases of schizophrenia in the markets under study (i.e., United States, United Kingdom, France, and Germany). Despite the availability of 32 atypical and typical antipsychotic therapies, which are considered the standard of care for resolving the positive symptoms of schizophrenia, the majority of drug-treated patients experience symptom relapse or inadequate symptom remittance because of these therapies’ insufficient efficacy and/or intolerability (which can result in treatment discontinuation). Thus, within this mature and rapidly genericizing market, commercial opportunities exist for emerging therapies that improve upon current antipsychotics’ tolerability and/or efficacy.
Schizophrenia - Special Topics - Special Topics Evolving Market Dynamics In Schizophrenia US
The schizophrenia therapy market is dominated by oral and long-acting injectable (LAI) antipsychotics, which are primaril...
Schizophrenia - Special Topics - Special Topics: Agitation In Bipolar And Schizophrenia (US)
Agitation is a common behavioral aspect often associated with bipolar disorder (BPD) and schizophrenia. It often manifests in the form of tension, violence, or...
Schizophrenia - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
Schizophrenia is an often disabling psychiatric disease that usually requires long-term treatment. The primary goals of medical treatment for schizophrenia are to reduce the frequency and severity...
Schizophrenia - Unmet Need - Detailed, Expanded Analysis (Cognitive Impairment)
Although the schizophrenia drug market is crowded, no pharmacological agents are approved specifically to treat cognitive impairment associated with schizophrenia (